FDA cites an ‘ongoing review’ for Pfizer's blockbuster Xeljanz, with implications for the class
On Wednesday a Pfizer representative told Endpoints News that the pharma giant had no immediate plans to take any new actions related to the marketing of their blockbuster drug Xeljanz. But it’s not entirely in their hands.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
